Previous Article | Next Article 
Journal of Clinical Microbiology, May 2000, p. 1947-1952, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Development and Evaluation of a Molecular
Viability Assay for Pneumocystis carinii
Nancy
Maher,1
Sten
Vermund,1
Mark
Lasbury,2
C.-H.
Lee,2
Marilyn
Bartlett,2 and
Thomas
R.
Unnasch1,*
Division of Geographic Medicine and
Department of Environmental Health Sciences, University of Alabama
at Birmingham, Birmingham, Alabama,1 and
Department of Pathology and Laboratory Medicine, Indiana
University School of Medicine, Indianapolis, Indiana2
Received 21 December 1999/Returned for modification 29 January
2000/Accepted 16 February 2000
 |
ABSTRACT |
Despite recent declines in incidence, Pneumocystis
carinii pneumonia (PCP) remains the most commonly occurring
opportunistic illness among persons with AIDS in the United States.
While P. carinii DNA has been detected in patient
respiratory specimens and in air samples collected from various indoor
environments housing PCP patients, the viability of these organisms is
unknown. For this reason, we have developed and evaluated a molecular
viability assay for P. carinii. This method is based upon
the detection of P. carinii mRNA by a reverse
transcription-PCR that employs specific primers from a member of the
heat shock protein 70 family. Under optimal assay conditions, these
primers were capable of detecting as few as 100 viable trophozoites as
determined by ethidium bromide staining, while no signal was obtained
from 106 trophozoites killed by heat, desiccation, or UV
radiation. This assay was also capable of distinguishing P. carinii from other common fungi present in the air. Therefore,
this molecular viability assay may be useful in conjunction with
standard bioaerosol collection devices and procedures for the detection
of viable P. carinii collected from various indoor
environments. It may also be useful in confirming the presence of
viable trophozoites in respiratory specimens collected by noninvasive
techniques from putatively infected individuals.
 |
INTRODUCTION |
Despite the recent declines in
incidence due to widespread chemoprophylaxis and antiretroviral therapy
in immunosuppressed human immunodeficiency virus (HIV)-infected
individuals, Pneumocystis carinii pneumonia (PCP) is still
the most common opportunistic infection during the course of AIDS in
the United States (7). However, for those persons who cannot
tolerate antipneumocystis therapy, or who are unaware of their HIV
status, the risk of PCP remains high (41).
Basic knowledge of P. carinii ecology and epidemiology is
still lacking. The once widely accepted theory of PCP reactivation in
persons with severe immunosuppression has come into question with
recent studies providing evidence to support the hypothesis that most
episodes of PCP result from a de novo acquisition. Support for this new
hypothesis includes epidemiological studies of hospital outbreaks
(8, 13, 16), animal studies of airborne transmission and
limited persistence after primary infections (9, 17, 34, 38,
39), the absence of P. carinii in respiratory samples collected from healthy individuals as well as asymptomatic HIV-infected individuals (28, 30, 31), and the demonstration that strain types of P. carinii isolated from patients during subsequent
episodes of infection differ approximately 50% of the time (20,
21, 36).
While airborne transmission of P. carinii appears likely,
the source of infective organisms remains largely unproven. It has been
hypothesized that an important source of P. carinii is
patients with patent PCP, who act as amplifiers and then shed large
numbers of viable organisms into their immediate environment. This
shedding would result in local concentrations of P. carinii
that considerably exceed the levels found in uncontaminated
environments. This conclusion is suggested from the facts that P. carinii sp. f. hominis DNA has been frequently detected
in low-volume air samples collected from the environments of PCP
patients and that it has rarely been detected in low-volume air samples
collected from indoor environments not recently housing a PCP patient
or from the outdoors (3, 5, 29). Furthermore, P. carinii sp. f. hominis strain types detected in air
samples collected from PCP patient hospital rooms matched the strain
types isolated from the same PCP patients in 12 of 14 instances
(3).
It has also been hypothesized that P. carinii is ubiquitous,
occurring at low levels in the general environment. Evidence for this
hypothesis comes from studies in which both human and rat P. carinii DNAs have been detected in large-volume air samples collected from the outdoor air (40) and in which the
seroprevalence of antibodies against P. carinii found in
young children has been high (32).
The method of choice for the diagnosis of PCP involves collection of
specimens by either induction of sputum or bronchoalveolar lavage
(BAL), followed by microscopic visualization of P. carinii trophozoites and/or cysts. The sensitivity of microscopic examination of induced sputum has been shown to be variable. For this reason, it
has been recommended that BAL be performed on patients presenting with
symptoms of PCP but who exhibit a negative induced-sputum sample
(41). On the other hand, because of the intrusiveness of
these techniques, many clinicians empirically treat suspected PCP cases
with antipneumocystis drugs, although this has been demonstrated to be
a highly nonspecific approach (6). Recent studies have
demonstrated that P. carinii DNA can be detected in oral
wash samples by PCR (2, 15, 37). This technique represents a
less invasive method for diagnosing the presence of P. carinii organisms in presumptively infected individuals, providing
a strong incentive to demonstrate organism viability in these samples.
Although it is possible to detect P. carinii DNA by PCR in
environmental and clinical samples, DNA detection gives no indication of organism viability. It is therefore unclear what the above-mentioned results mean in terms of potential risk for susceptible individuals, potential exposure control measures, or the ecology of P. carinii. In order to evaluate the viability of P. carinii organisms collected from environmental and clinical
sources, we have developed a molecular viability assay to be used in
conjunction with standard bioaerosol collection techniques as well as
noninvasive clinical specimen collection methods.
 |
MATERIALS AND METHODS |
P. carinii sp. f. carinii culture.
P. carinii sp. f. carinii trophozoites and cysts
were harvested from preparations derived from spinner-flask cultures
prepared as previously described (22). Briefly, mixed
cultures of P. carinii sp. f. carinii
trophozoites and cysts isolated from infected rat lungs were grown in a
spinner-flask culture containing human embryonic cells sheeted to
Cytodex microcarrier beads. An approximate fivefold increase in the
number of organisms is typically seen in 7 days, as determined by
organism count, antigen detection, and DNA quantification. These
cultures consist primarily of trophozoites (95 to 99%), with a small
proportion of cysts (1 to 5%).
P. carinii sp. f. carinii isolation and
cyst enrichment.
P. carinii sp. f. carinii cysts
and trophozoites were isolated from the infected lungs of
immunosuppressed Sprague-Dawley rats as previously described
(26). A cyst enrichment protocol was then performed on the
isolated organisms. Isolated organisms were resuspended in 1 ml of
phosphate-buffered saline (PBS; 1.5 mM KH2PO4,
8.1 mM Na2HPO4 [pH 7.4], 1.5 mM KCl, 137 mM
NaCl; Life Technologies) and subjected to one freeze-thaw cycle,
followed by centrifugation at 5,000 × g for 10 min at
4°C. The pelleted organisms were then resuspended in a 0.1× PBS
solution containing 0.1% sodium dodecyl sulfate (SDS) for 10 min at
25°C. The remaining cysts were pelleted at 5,000 × g
for 10 min at 4°C and then washed five times in PBS to remove cell
debris and free nucleic acids. This protocol typically yielded
approximately 59% of the original cyst population while removing most
host cells and trophozoites.
Microscopic organism enumeration and viability assessment.
Before RNA extraction from either a cyst-enriched preparation or a
spinner-flask harvest, organism density and viability were determined
microscopically. Organism density was assessed as described by Lee et
al. (22). Viability was assessed essentially as described by
Kaneshiro et al. (18). Briefly, the fluorescent dye
calcein-acetoxy methyl ester (Molecular Probes, Inc., Eugene, Oreg.)
was used in conjunction with the nucleic acid stain ethidium bromide
(EB). An aliquot from the P. carinii sp. f.
carinii preparation was placed in 200 µl of PBS, to which
calcein-acetoxy methyl ester was added for a final concentration of 13 µM and EB was added for a final concentration of 25 µM. The
organisms were placed in an incubator at 37°C for 30 min, after which
time they were examined by epifluorescence microscopy. Organisms that
fluoresced green were considered viable, and those that fluoresced red
were considered nonviable.
RNA extraction.
Total RNA was extracted from P. carinii sp. f. carinii trophozoites and cysts derived
from spinner-flask cultures by employing a commercially available RNA
isolation kit (RNeasy; Qiagen Inc., Valencia, Calif.), according to the
manufacturer's instructions. Total RNA was extracted from the
enriched-cyst preparation derived from rat lung as well as three
species of fungi: Aspergillus niger, Saccharomyces
cerevisiae, and Penicillium chrysogenum. A. niger and Penicillium sp. were examined because they
are soil fungi that are commonly present in indoor air (14,
23), while S. cerevisiae was chosen because it is
commonly present in indoor environments and because it has been shown
to be genetically very similar to P. carinii
(12). The cysts and fungal harvests were incubated in a
solution containing 100 mM NaCl, 40 mM EDTA, 0.2% SDS, and 200 µg of
proteinase K per ml for 6 h at 37°C. A commercially available
guanidinium isothiocyanate solution (RNAzol B; Teltest, Inc.,
Friendswood, Tex.) was then added directly to the mixture, and total
RNA isolation was carried out according to the manufacturer's instructions. The mRNA species were then purified from the total RNA
preparation by adsorption to oligo(dT) beads (Oligotex; Qiagen Inc.) by
following the manufacturer's instructions.
RT-PCR assay.
mRNA-specific primers from a member of the
P. carinii sp. f. carinii heat shock protein 70 (HSP70) multigene family (PcSA1; GenBank accession number U80967
[35]) were designed for use in a reverse
transcription-PCR (RT-PCR) assay to assess organism viability. The
coding primer (5'-TTGAGAAAGCAATTGGTATT-3') was designed to
cross the second intron splice site found in the PcSA1 gene. The
sequence of the noncoding primer was 5'-CTGCTGCAGTAGGCTCATTG-3'. RNA preparations prepared as described above were initially
annealed in a solution containing a 4 µM concentration of the
noncoding primer by heating to 70°C for 15 min and cooling to 0°C
for 5 min. The solution containing the annealed complex was brought to
a final volume of 10 µl in a solution containing 50 mM Tris-HCl (pH
8.3), 75 mM KCl, 5 mM MgCl2, 10 mM dithiothreitol, a 0.5 mM concentration (each) of dATP, dCTP, dGTP, and dTTP, 10 U of RNasin RNase inhibitor (Promega Inc., Madison, Wis.), and 100 U of Superscript II RNase H
reverse transcriptase (BRL Life Technologies,
Gaithersburg, Md.). RT reaction mixtures were incubated at 45°C for
50 min and then at 70°C for 10 min. After the completion of the cDNA
first-strand synthesis, the reaction mixture was diluted to 50 µl for
PCR amplification. The final PCR solution contained 60 mM Tris-HCl (pH
8.5), 15 mM (NH4)2SO4, 3.5 mM
MgCl2, a 0.5 µM concentration of each primer, a 100 µM
concentration (each) of dATP, dGTP, dCTP, and dTTP, and 2.5 U of
Amplitaq (Applied Biosystems Inc., Branchburg, N.J.). The reaction
mixture was then overlaid with 50 µl of mineral oil and subjected to
40 cycles of 94°C for 1 min, 50°C for 1 min, and 72°C for 1 min,
followed by an incubation at 72°C for 7 min. RT-PCR products were
electrophoresed on 1.5% agarose gel and detected after being stained
with EB.
RT-PCR products derived from P. carinii were gel purified
and cloned into the pCR2.1 vector (Invitrogen Inc., La Jolla, Calif.). The clones were then manually sequenced, and their identities were
confirmed by comparison with the PcSA1 gene sequence.
Southern blot hybridization.
A Southern blot was prepared by
capillary blotting an agarose gel containing the PcSA1 PCR products
onto Hybond nylon membrane (Amersham Life Sciences Inc., Little
Chalfont, Buckinghamshire, England). The blot was hybridized in the
formamide buffer recommended by the manufacturer at 42°C using
radiolabeled PCR products derived from a pure culture of P. carinii sp. f. carinii as a probe. Following hybridization, the membrane was washed twice at 50°C in a solution of
15 mM NaCl, 1.5 mM sodium citrate, and 0.1% SDS.
 |
RESULTS |
mRNA-specific primers from a member of the P. carinii
sp. f. carinii HSP70 multigene family (PcSA1) were designed
for use in an RT-PCR assay to assess organism viability. While the
majority of the HSP70 genes in P. carinii are constitutively
expressed, expression of PcSA1 is upregulated by brief exposure to
moderate heat (35). The 5' (coding orientation) primer was
designed from the cDNA sequence so that the sequence of the primer
included the second intron splice site in the PcSA1 sequence (GenBank
accession number U80967) (Fig. 1A). The
3' (noncoding) primer was derived from the third exon (Fig. 1A). Use of
these primers in an RT-PCR assay employing total RNA extracted from
roughly 106 trophozoites isolated from a spinner-flask
culture resulted in the production of a 530-bp PCR product, equivalent
in size to that predicted from analysis of the mature mRNA (Fig. 1B).
DNA sequence analysis of this product confirmed that it was derived from the mature PcSA1 transcript. Furthermore, the 530-bp product was
not obtained from mRNA extracted from uninfected rat lungs, providing
additional evidence that this product was derived from P. carinii and not host cell mRNA (data not shown). As expected, the
530-bp product was also absent from reaction mixtures lacking reverse
transcriptase, as the design of the coding primer across the intron
splice site prevented the amplification of this product from
contaminating P. carinii genomic DNA (Fig. 1B).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Specific amplification of PcSA1 sequences from P. carinii mRNA. (A) Design of primers for the PcSA1 RT-PCR assay.
The 5' (coding orientation) primer crosses a 58-bp intron to prevent
the amplification of contaminating genomic DNA derived from P. carinii. The exon sequences are shown in uppercase letters, and
the intron sequence is shown in lowercase letters. (B) Results from the
PcSA1 RT-PCR assay. Lane 1, RT-PCR carried out on total RNA extracted
from 106 P. carinii organisms derived from a
spinner-flask culture; lane 2, control RT-PCR lacking reverse
transcriptase carried out on total RNA extracted from 106
P. carinii organisms derived from a spinner-flask culture;
lane 3, PCR negative control. +RT, with reverse transcriptase; RT,
without reverse transcriptase.
|
|
In order to determine the sensitivity of the assay, RNAs extracted from
serial dilutions of spinner-flask-cultured organisms were employed as
templates in the RT-PCR assay. The assay was found to detect as few as
102 trophozoites as determined by EB staining (Fig.
2). To examine the specificity of the
RT-PCR for the detection of viable organisms (i.e., the ability of the
assay to distinguish viable from nonviable organisms), four aliquots,
each containing 106 viable trophozoites, were prepared.
Total RNA was extracted from an untreated dilution series prepared from
one aliquot (104 to 102 trophozoites), while
the other three aliquots of trophozoites were subjected either to heat
(autoclave), desiccation (left on bench top for 1 week), or UV light
exposure (left under a germicidal lamp for 24 h). Loss of
viability in these treated samples was confirmed by microscopy, as
described in Materials and Methods. Total RNA was then extracted from
each of the treated samples in the same manner as for the untreated
sample. A positive signal was obtained from the aliquot containing
102 viable trophozoites, while no signal was obtained from
any of the treated samples (Fig. 3).
Thus, the assay was capable of distinguishing 102 viable
P. carinii trophozoites from 106 nonviable
P. carinii trophozoites.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 2.
Sensitivity of the PcSA1 RT-PCR. RT-PCRs were carried
out on total RNA preparations prepared from log-unit dilutions of
viable P. carinii. Lane 6, 106 P. carinii organisms; lane 5, 105 P. carinii
organisms; lane 4, 104 P. carinii organisms;
lane 3, 103 P. carinii organisms; lane 2, 102 P. carinii organisms; lane 1, 101 P. carinii organisms; lane RT, without
reverse transcriptase (RNA from 106 organisms); lane ,
PCR negative control.
|
|

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 3.
Discrimination of viable from nonviable organisms by the
PcSA1 RT-PCR. RT-PCR assays were carried out as described in Materials
and Methods by employing RNAs extracted from treated cultures of
P. carinii as templates. Lane 1, RNA derived from
104 untreated P. carinii organisms; lane 2, RNA
derived from 103 untreated organisms; lane 3, RNA derived
from 102 untreated organisms; lane 4, RNA derived from
106 P. carinii organisms killed by desiccation;
lane 5, RNA derived from 106 organisms killed by heat; lane
6, RNA derived from 106 organisms killed by UV light; lane
7, no RNA; lane 8, PCR negative control.
|
|
One major application of a molecular viability assay for P. carinii will be to detect the presence of viable organisms in the
environment. It was therefore of interest to explore the level of
species specificity of the RT-PCR. To accomplish this, the P. carinii primers were employed to attempt to amplify a related sequence from RNAs prepared from three different species of
ascomycetous fungi as described in Materials and Methods. The PcSA1
primers amplified a small fragment from Penicillium
chrysogenum and a fragment derived from S. cerevisiae
of approximately the same size as that amplified from P. carinii (Fig. 4A). However, the band
derived from S. cerevisiae was easily distinguished from that of P. carinii on the basis of hybridization with the
bona fide P. carinii PCR product (Fig. 4B).

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
Species specificity of the PcSA1 RT-PCR. RT-PCRs were
carried out on fungal RNA preparations prepared as described in
Materials and Methods. (A) EB-stained gel of PCR products; (B) Southern
blot of the gel shown in panel A probed with the labeled PcSA1 PCR
product. In each panel, lane 1 contains RNA extracted from P. carinii, lane 2 contains RNA extracted from S. cerevisiae, lane 3 contains RNA extracted from Penicillium
chrysogenum, and lane 4 contains RNA extracted from A. niger.
|
|
Since spinner-flask cultures consisted primarily of trophozoites (95 to
99%), it was unlikely that the small number of cysts in the harvest
preparations contributed much to the results obtained from the
spinner-flask cultures. Therefore, it was necessary to determine if the
heat shock RT-PCR assay was capable of detecting a preparation
primarily composed of cysts. To accomplish this, P. carinii
organisms were isolated from rat lungs with overt P. carinii
infection. The mixed-life cycle preparation was then treated in order
to isolate the cysts from the trophozoites, as described in Materials
and Methods. Bright-field microscopic examination of the cyst-enriched
preparation revealed no intact trophozoites in 20 fields, while the
cyst concentration was estimated to be at least 107/ml.
Together, these data suggested that the enriched-cyst preparation contained less than 0.1% trophozoite contamination. Epifluorescence microscopic examination of the preparation suggested that greater that
80% of the cysts in the enriched preparation were viable.
Total RNA was isolated from the enriched-cyst preparation as described
in Materials and Methods, and poly(A)+ RNAs purified from
the total RNA preparations were used as templates in the RT-PCR. The
additional purification step [poly(A)+ RNA isolation] was
found to be necessary to eliminate inhibitors of the RT reaction found
to be present in the total RNA preparations prepared from the enriched
cysts (data not shown). Following RT-PCR, the poly(A)+ RNA
preparation from the enriched-cyst preparation resulted in material
that supported the amplification of the PcSA1 product (Fig.
5).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 5.
Detection of P. carinii cysts by the PcSA1
RT-PCR. Lane 1, poly(A)+ mRNA extracted from a
cyst-enriched preparation; lane 2, RNA derived from a spinner-flask
culture; lane 3, cyst-enriched preparation of RNA amplified in the
absence of reverse transcriptase; lane 4, PCR negative control.
|
|
 |
DISCUSSION |
The rationale for the viability assay described above was that
mRNA molecules, as opposed to DNA or rRNA, are usually unstable following the death of an organism. By designing primers that span an
intron splice site in the PcSA1 sequence, we anticipated that only
intact mRNA molecules would serve as a template in the RT-PCR and that
these molecules would be labile following the death of the organism.
The data described above suggest that this was the case. The RT-PCR
assay was capable of detecting as few as 102 viable
trophozoites as determined by EB staining. In contrast, 106
nonviable trophozoites killed by either high heat, desiccation, or UV
exposure produced no signal in the RT-PCR assay. This is significant,
as the last two methods of killing represent the two most important
mechanisms resulting in the loss of viability of airborne
microorganisms (10). Apart from its ability to distinguish viable and nonviable P. carinii, this RT-PCR assay can
distinguish between viable P. carinii and other fungi that
commonly occur in the indoor environment. Both Aspergillus
and Penicillium sp. are commonly present in the indoor
environment (14), a finding confirmed with our own air
sampling of an urban indoor residence, in which moderate levels of
viable A. niger, Aspergillus fumigatus, and
Penicillium were found (data not shown).
Although most of the experiments carried out in the work described
above involved trophozoites obtained from spinner-flask-cultured organisms, the assay was also capable of detecting the PcSA1 transcript in a cyst-enriched preparation obtained directly from an infected rat
lung. Although this preparation was highly enriched for cysts, we
cannot rule out the possibility that the positive signal obtained from
this preparation resulted from contamination of the cyst preparation,
either with intact trophozoites or with residual mRNA released from the
lysed trophozoites.
While the life cycle stage involved in airborne transmission is
unknown, the likely candidate would be the P. carinii cyst due the structure of its cell wall, which possibly allows for protection against environmental stressors such as desiccation. Thus,
determining how well this RT-PCR assay assesses cyst viability is key
to its use with environmental samples. There are precedents for use of
the RT-PCR in assessing the viability of both Giardia cysts
(1, 19) and Cryptosporidium oocysts collected
from environmental samples (19). These assays all exploited
the heat shock responses of the two organisms, distinguishing viable
from nonviable cysts by detecting the heat shock transcript by RT-PCR after heat treatment.
Culturing of air samples collected from the environment is standard
procedure in the field of aerobiology when the presence of viable
biological agents is assessed (11). Thus, one possible approach for viable P. carinii cyst detection might involve
short-term (<24 h) culture of cysts collected from the environment by
bioaerosol collection methods such as filtration or liquid impingement.
This would allow for maturation of the eight intracystic bodies to trophozoites. RNAs extracted from the cultures containing the newly
emerged trophozoites could then be used as templates in the RT-PCR assay.
When bacteria are selectively sampled, a fungicide is added to the
medium, and when fungal spores are selectively sampled, antibiotics are
added to the medium. Unlike any other known species of fungus, P. carinii lacks the steroid ergosterol in its cell wall. Thus, it is
not susceptible to the class of fungicidal drugs that inhibit
ergosterol biosynthesis (4). Therefore, antibiotics and
antifungals such as the imidazole drugs can be added to a short-term
culture of P. carinii, allowing for its growth while preventing the growth of other fungi and bacteria collected in the sample.
One additional application of this viability assay may be in clinical
diagnosis of PCP. It is possible to envision a two-step system to
utilize the RT-PCR in combination with the DNA-based PCR for this
purpose. The DNA-based PCR might first be used to detect P. carinii DNA in patient oral wash samples. If evidence for the
presence of P. carinii DNA is obtained, positive individuals can be retested by employing the RT-PCR assay to confirm the presence of viable trophozoites, which are the most prevalent life cycle stage
found in an infected host (24). This strategy might
represent a sensitive and specific diagnostic protocol that is much
less invasive than BAL or induction of sputum. This approach might also
prove useful in detecting low levels of viable organisms in the face of
highly active therapies where organism burdens may be lower than in
untreated disease.
Additional work on this assay will be needed before it can used as a
reliable tool in a field study of the occurrence of viable P. carinii sp. f. hominis in the environment. Issues such
as organism recovery efficiency from bioaerosol collection devices and
potential environmental interference must be worked out. Finally, the
system must be adapted for use with the human-specific variant of
P. carinii. With the recent successes in the development of
a human P. carinii culture system (27), this
should be relatively straightforward.
Determination of organism viability does not prove infectiousness.
However, determining where, when, and under what circumstances viable
P. carinii occurs in the environment will help to narrow down the list of potential sources of infection. If the theory of PCP
patients contaminating indoor environments with infectious organisms
holds true, then there are many infection control approaches that can
be used to limit exposure of at-risk individuals to the organism. Given
the potential for antibiotic resistance (25) and the
toxicity associated with P. carinii prophylaxis among HIV
patients (33), exposure prevention may be preferable if person-to-person transmission can be confirmed as an important mode of
infection in studies employing the molecular viability assay described herein.
 |
ACKNOWLEDGMENT |
This work was supported by National Institutes of Health grant
R01 (AI54586 01 A1).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Geographic Medicine, University of Alabama at Birmingham, BBRB 203, 1530 3rd Ave. South, Birmingham, AL 35294-2170. Phone: (205) 975-7601. Fax: (205) 933-5671. E-mail:
trunnasch{at}geomed.dom.uab.edu.
 |
REFERENCES |
| 1.
|
Abbaszadegan, M. H.,
M. S. Huber,
C. P. Gerba, and I. L. Pepper.
1997.
Detection of viable Giardia cysts by amplification of heat shock-induced mRNA.
Appl. Environ. Microbiol.
63:324-328[Abstract].
|
| 2.
|
Atzori, C.,
F. Agostini,
G. Gubertini, and A. Cargneal.
1996.
Diagnosis of PCP by ITS nested PCR on noninvasive oropharyngeal samples.
J. Eukaryot. Microbiol.
43(5):44[CrossRef] Suppl.
|
| 3.
|
Bartlett, M. S.,
J.-J. Lu,
C.-H. Lee,
P. J. Durant,
S. F. Queener, and J. W. Smith.
1996.
Types of Pneumocystis carinii detected in air samples.
J. Eukararyot. Microbiol.
43(5):44 Suppl.
|
| 4.
|
Bartlett, M. S.,
S. F. Queener,
M. M. Shaw,
J. D. Richardson, and J. W. Smith.
1994.
Pneumocystis carinii is resistant to imidazole antifungal agents.
Antimicrob. Agents Chemother.
38:1859-1861[Abstract/Free Full Text].
|
| 5.
|
Bartlett, M. S.,
S. H. Vermund,
R. R. Jacobs,
P. Durant,
M. M. Shaw,
J. W. Smith,
X. Tang,
J.-J. Lu,
B.-H. Li,
S. Jin, and C.-H. Lee.
1997.
Detection of Pneumocystis carinii DNA in air samples: likely environmental risk to susceptible persons.
J. Clin. Microbiol.
35:2511-2513[Abstract].
|
| 6.
|
Baughman, R. P.,
M. N. Dohn, and P. T. Frame.
1994.
The continuing utility of bronchoalveolar lavage to diagnose opportunistic infection in AIDS patients.
Am. J. Med.
97:515-522[CrossRef][Medline].
|
| 7.
|
Centers for Disease Control and Prevention.
1997.
HIV/AIDS surveillance report 9 2.
Centers for Disease Control and Prevention, Atlanta, Ga.
|
| 8.
|
Chave, J. P.,
J. P. Wauters,
G. Van Melle, and P. Francioli.
1991.
Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant recipients.
AIDS
5:927-932[Medline].
|
| 9.
|
Chen, W.,
F. Gigliotti, and A. G. Harmsen.
1993.
Latency is not an inevitable outcome of infection with Pneumocystis carinii.
Infect. Immun.
61:237-242.
|
| 10.
|
Cox, C. S.
1995.
Stability of airborne microbes and allergens, p. 77-98.
In
C. S. Cox, and C. M. Wathes (ed.), Bioaerosols handbook. CRC Press, Boca Raton, Fla.
|
| 11.
|
Dillon, H. K.,
P. A. Heinsohn, and J. D. Miller.
1996.
AIHA: field guide for the determination of biological contaminants in the environment.
American Industrial Hygiene Association, Fairfax, Va.
|
| 12.
|
Edman, J. C.,
J. A. Kovacs,
H. Masur,
D. V. Santi,
H. J. Elwood, and M. L. Sogun.
1988.
Ribosomal RNA sequences show Pneumocystis to be a member of the fungi.
Nature
334:519-522[CrossRef][Medline].
|
| 13.
|
Goesch, T. R.,
G. Gotz,
K. H. Stellbrunk,
H. Albrecht,
H. J. Weh, and D. K. Hossfield.
1990.
Possible transfer of Pneumocystis carinii between immunodeficient patients.
Lancet
336:627[Medline].
|
| 14.
|
Hay, R. J.,
Y. M. Clayton, and J. M. Goodley.
1995.
Fungal aerobiology: how, when and where?
J. Hosp. Infect.
30(Suppl.):352-357.
|
| 15.
|
Helweglarsen, J.,
J. S. Jensen,
T. Benfield,
U. G. Svendsen,
J. D. Lundgren, and B. Lundgren.
1998.
Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples.
J. Clin. Microbiol.
36:2068-2072[Abstract/Free Full Text].
|
| 16.
|
Hennequin, C.,
B. Page,
P. Roux,
C. Legendre, and H. Kreis.
1995.
Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit.
Eur. J. Clin. Microbiol. Infect. Dis.
14:122-126[CrossRef][Medline].
|
| 17.
|
Hughes, W. T.
1982.
Natural mode of acquisition for de novo infection with Pneumocystis carinii.
J. Infect. Dis.
145:842-848[Medline].
|
| 18.
|
Kaneshiro, E. S.,
M. A. Wider,
Y.-P. Wu, and M. T. Cushion.
1993.
Reliability of calcein acetoxy methyl ester and ethidium homodimer or propidium iodide for viability assessment of microbes.
J. Microbiol. Methods
17:1-16.
|
| 19.
|
Kaucner, C., and T. Stinear.
1998.
Sensitive and rapid detection of viable Giardia cysts and Crytosporidium parvum oocysts in large-volume water samples with wound fiberglass cartridge filters and reverse transcription-PCR.
Appl. Environ. Microbiol.
64:1743-1749[Abstract/Free Full Text].
|
| 20.
|
Keely, S. P., and J. R. Stringer.
1997.
Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci.
J. Clin. Microbiol.
35:2745-2747[Abstract].
|
| 21.
|
Keely, S. P.,
J. R. Stringer,
R. P. Baughman,
M. J. Linke,
P. D. Walzer, and A. G. Smulian.
1995.
Genetic variation among Pneumocystis carinii hominis isolates in recurrent Pneumocystis.
J. Infect. Dis.
172:595-598[Medline].
|
| 22.
|
Lee, C.-H.,
N. L. Bauer,
M. M. Shaw,
M. M. Durkin,
M. S. Bartlett,
S. F. Queener, and J. W. Smith.
1993.
Proliferation of rat Pneumocystis carinii on cells sheeted on microcarrier beads in spinner flasks.
J. Clin. Microbiol.
31:1659-1662[Abstract/Free Full Text].
|
| 23.
|
Levetin, E.
1995.
Fungi, p. 104-107.
In
H. Burge (ed.), Bioaerosols. Lewis Publishers, Ann Arbor, Mich.
|
| 24.
|
Levine, S. J.
1996.
Pneumocystis carinii.
Clin. Chest Med.
17:665-695[CrossRef][Medline]. (Review.)
|
| 25.
|
Mei, Q.,
S. Gurunathan,
H. Masur, and J. A. Kovacs.
1998.
Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene.
Lancet
351:1631-1632[Medline].
|
| 26.
|
Merali, S., and A. B. Clarkson, Jr.
1996.
Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL- -difluoromethylornithine.
Antimicrob. Agents Chemother.
40:973-978[Abstract].
|
| 27.
|
Merali, S.,
U. Frevert,
J. H. Williams,
K. Chin,
R. Bryan,
J. Allen, and B. Clarkson.
1999.
Continuous axenic cultivation of Pneumocystis carinii.
Proc. Natl. Acad. Sci. USA
96:2402-2407[Abstract/Free Full Text].
|
| 28.
|
Millard, P. R., and A. R. Heryet.
1988.
Observation favouring Pneumocystis carinii as a primary infection: a monoclonal antibody study on paraffin sections.
J. Pathol.
154:365-368[CrossRef][Medline].
|
| 29.
|
Olsson, M.,
C. Lidman,
S. Latouche,
A. Bjorkman,
P. Roux,
E. Linder, and M. Wahlgren.
1998.
Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments.
J. Clin. Microbiol.
36:1737-1740[Abstract/Free Full Text].
|
| 30.
|
Ongibene, F. P.,
J. Masur,
P. Rogers,
A. F. Travis,
L. Suffredini,
I. Feuerstein,
V. J. Gill,
B. F. Baird,
J. S. Carrasquillo,
J. E. Parrillo,
H. C. Lane, and J. H. Shelmamer.
1988.
Nonspecific interstitial pneumonitis without evidence of Pneumocystis carinii in asymptomatic patients infected with human immunodeficiency virus (HIV).
Ann. Intern. Med.
109:874-878.
|
| 31.
|
Peters, S. E.,
A. E. Wakefield,
K. Sinclair,
P. R. Millard, and J. M. Hopkins.
1992.
A search for Pneumocystis carinii in post mortum lungs by DNA amplification.
J. Pathol.
166:195-198[CrossRef][Medline].
|
| 32.
|
Pifer, L. L.,
W. T. Hughes,
S. Stagno, and D. Woods.
1978.
Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.
Pediatrics
61:35-41[Abstract/Free Full Text].
|
| 33.
|
Ryan, C.,
M. Madalon,
D. W. Wortham, and F. M. Graziano.
1998.
Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature.
Wis. Med. J.
97(5):23-27.
|
| 34.
|
Sepkowitz, K.,
N. Schulager,
T. Godwin,
C. Armstrong, and R. Bucula.
1993.
DNA amplification in experimental pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential P. carinii carrier states.
J. Infect. Dis.
168:421-426[Medline].
|
| 35.
|
Stedman, T. T.,
D. R. Butler, and G. A. Buck.
1998.
The HSP70 gene family in Pneumocystis carinii: molecular and phylogenetic characterization of cytoplasmic members.
J. Eukaryot. Microbiol.
45:589-599[Medline].
|
| 36.
|
Tsolaki, A. G.,
R. F. Miller,
A. P. Underwood,
S. Bajeri, and A. E. Wakefield.
1996.
Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia.
J. Infect. Dis.
174:141-156[Medline].
|
| 37.
|
Tsolaki, A. G.,
R. F. Miller, and A. E. Wakefield.
1999.
Oropharyngeal samples for genotyping and monitoring response to treatment in AIDS patients with Pneumocystis carinii pneumonia.
J. Med. Microbiol.
48:897-905[Abstract/Free Full Text].
|
| 38.
|
Vargas, S. L.,
W. T. Hughes,
A. E. Wakefield, and H. S. Oz.
1995.
Limited persistence and subsequent elimination of Pneumocystis carinii from the lungs after P. carinii pneumonia.
J. Infect. Dis.
172:506-510[Medline].
|
| 39.
|
Vogel, P.,
C. J. Miller,
L. L. Lowenstine, and A. A. Lackner.
1993.
Evidence of horizontal transmission of Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus monkeys.
J. Infect. Dis.
168:836-843[Medline].
|
| 40.
|
Wakefield, A. E.
1996.
DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora.
J. Clin. Microbiol.
34:1754-1759[Abstract].
|
| 41.
|
Wilken, A., and J. Feinberg.
1999.
Pneumocystis carinii pneumonia: a clinical review.
Am. Family Phys.
60:1699-1708[Medline].
|
Journal of Clinical Microbiology, May 2000, p. 1947-1952, Vol. 38, No. 5
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Icenhour, C. R., Kottom, T. J., Limper, A. H.
(2006). Pneumocystis Melanins Confer Enhanced Organism Viability. Eukaryot Cell
5: 916-923
[Abstract]
[Full Text]
-
Larsen, H. H., Kovacs, J. A., Stock, F., Vestereng, V. H., Lundgren, B., Fischer, S. H., Gill, V. J.
(2002). Development of a Rapid Real-Time PCR Assay for Quantitation of Pneumocystis carinii f. sp. carinii. J. Clin. Microbiol.
40: 2989-2993
[Abstract]
[Full Text]
-
Okeke, C. N., Tsuboi, R., Ogawa, H.
(2001). Quantification of Candida albicans Actin mRNA by the LightCycler System as a Means of Assessing Viability in a Model of Cutaneous Candidiasis. J. Clin. Microbiol.
39: 3491-3494
[Abstract]
[Full Text]